The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Local senolysis in aged mice only partially replicates the benefits of systemic senolysis
Open accessAbstract
Clearance of senescent cells (SnCs) can prevent several age-related pathologies, including bone loss. However, the local versus systemic roles of SnCs in mediating tissue dysfunction remain unclear. Thus, we developed a mouse model (p16-LOX-ATTAC) that allowed for inducible SnC elimination (senolysis) in a cell-specific manner and compared the effects of local versus systemic senolysis during aging using bone as a prototype tissue. Specific removal of Sn osteocytes prevented age-related bone loss at the spine, but not the femur, by improving bone formation without affecting osteoclasts or marrow adipocytes. By contrast, systemic senolysis prevented bone loss at the spine and femur and not only improved bone formation, but also reduced osteoclast and marrow adipocyte numbers. Transplantation of SnCs into the peritoneal cavity of young mice caused bone loss and also induced senescence in distant host osteocytes. Collectively, our findings provide proof-of-concept evidence that local senolysis has health benefits in the context of aging, but, importantly, that local senolysis only partially replicates the benefits of systemic senolysis. Furthermore, we establish that SnCs, through their senescence-associated secretory phenotype (SASP), lead to senescence in distant cells. Therefore, our study indicates that optimizing senolytic drugs may require systemic instead of local SnC targeting to extend healthy aging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although as noted earlier, P1NP could also justifiably have been chosen as our primary outcome based on our animal data13,14.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the observation from our preclinical studies that senescent osteocytes remained reduced in mice following 4 months of monthly D + Q administration, with similar findings noted in our genetic clearance models13,14.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sost mRNA levels are reduced in osteocyte-enriched bone samples in old mice following senescent cell clearance13,14”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Therefore, the aim of this phase 2 RCT was to examine whether our findings in aged mice demonstrating both anabolic and antiresorptive effects of intermittent senolytic therapy on bone metabolism13,14, were applicable to humans.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Traditionally, these models contain luminescent or fluorescent reporter systems yielding increased signal dependent upon the expression level of p21 or p168,83,104–107.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [83]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., Clark, N. R., & Ma’ayan, A. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-128 · Cited by 7,814
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationGeroscience: Linking Aging to Chronic Disease
Kennedy, B. K., Berger, S. L., Brunet, A., Campisi, J., Cuervo, A. M., Epel, E. S., Franceschi, C., Lithgow, G. J., Morimoto, R. I., Pessin, J. E., et al. (2014) · Cell · doi:10.1016/j.cell.2014.10.039 · Cited by 2,764
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 1×
“These findings inspired the discovery of a class of drugs known as senolytics that selectively kill SnCs as a therapeutic approach to extend healthy aging (11).”
Self-citationBonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287 · cited 1×
“…mice crossed with the heterogeneity of most tissues, bone is abundantly populated by osteocytes (comprising >95% of all skeletal cells) (13); (b) spatial and temporal control of precise gene manipulations in osteocytes using the Cre-loxP system is facilitated by a well-characterized…”
Senolytics improve physical function and increase lifespan in old age
Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., Inman, C. L., Ogrodnik, M. B., Hachfeld, C. M., Fraser, D. G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0092-9 · Cited by 2,287 · cited 3×
“…has previously shown that transplanted cells (both Sn and non-Sn control) remain detectable in vivo for only up to 40 days after transplantation (42), we next asked whether at 60 days after SnC transplantation, beyond the point these cells are no longer detectable, the transplanted SnCs induced…”
Self-citationHulsen, T., de Vlieg, J., & Alkema, W. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-488 · Cited by 1,674
Ink4a/Arf expression is a biomarker of aging
Krishnamurthy, J., Torrice, C., Ramsey, M. R., Kovalev, G. I., Al-Regaiey, K., Su, L., & Sharpless, N. E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22475 · Cited by 1,486 · cited 1×
“With aging, SnCs have increased expression of p16 Ink4a in several mammalian tissues (20), whereas p21 Cip1 seems to be induced by cells under acute duress leading to senescence in other circumstances (21), including tissue repair (22, 23).”
Facing up to the global challenges of ageing
Partridge, L., Deelen, J., & Slagboom, P. E. (2018) · Nature · doi:10.1038/s41586-018-0457-8 · Cited by 1,475
Cited by
SenNet recommendations for detecting senescent cells in different tissues
Suryadevara, V., Hudgins, A. D., Rajesh, A., Pappalardo, A., Karpova, A., Dey, A. K., Hertzel, A., Agudelo, A., Rocha, A., Soygur, B., et al. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00738-8 · Cited by 408
“In both ageing and the disease states listed above, skeletal cellular senescence can also be observed through histological staining of SA-β-gal activity 203 , SADS 93,200,204,205 and TAF 200,203,204 , typically in bone-embedded osteocytes 206 .”
Self-citationGuidelines for minimal information on cellular senescence experimentation in vivo
Ogrodnik, M., Carlos Acosta, J., Adams, P. D., d’Adda di Fagagna, F., Baker, D. J., Bishop, C. L., Chandra, T., Collado, M., Gil, J., Gorgoulis, V., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.059 · Cited by 376
Self-citationSenescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197
“The above models enable the elimination of all cell types, but there are models such as p16-LOX-ATTAC mice that allow for Cre-dependent elimination of a specific type of SnC to achieve local senolysis 191 .”
Hou, J., Chen, K.-X., He, C., Li, X., Huang, M., Jiang, Y., Jiao, Y., Xiao, Q.-N., He, W., Liu, L., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00694-0 · Cited by 164
“Elimination of senescent cells 8,43,44 has emerged as a plausible therapeutic approach for preventing, delaying or alleviating multiple diseases and age-related dysfunction 3,45–49 .”
Farr, J. N., Atkinson, E. J., Achenbach, S. J., Volkman, T. L., Tweed, A. J., Vos, S. J., Ruan, M., Sfeir, J., Drake, M. T., Saul, D., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03096-2 · Cited by 127
“…our previous studies in aged mice had demonstrated a reduction in bone resorption and increase in bone formation following seno-lytic treatment 13,14 , the choice of whether to assign CTx or P1NP as the primary endpoint was entirely arbitrary, particularly in the absence of any previous human…”
InfluentialSelf-citation
Metadata
- Authors
- Farr, J. N., Saul, D., Doolittle, M. L., Kaur, J., Rowsey, J. L., Vos, S. J., Froemming, M. N., Lagnado, A. B., Zhu, Y., Weivoda, M., Ikeno, Y., Pignolo, R. J., Niedernhofer, L. J., Robbins, P. D., Jurk, D., Passos, J. F., LeBrasseur, N. K., Tchkonia, T., Kirkland, J. L., Monroe, D. G., & Khosla, S.
- Affiliations
- Mayo Clinic (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Minnesota (US)
- Corresponding author
- Farr, Joshua N.
- Khosla, Sundeep
- ORCID
- Farr, Joshua N.
- Saul, Dominik
- Doolittle, Madison L.
- Kaur, Japneet
- Rowsey, Jennifer L.
- Froemming, Mitchell N.
- Lagnado, Anthony B.
- Zhu, Yi
- Weivoda, Megan
- Ikeno, Yuji
- Pignolo, Robert J.
- Niedernhofer, Laura J.
- Robbins, Paul D.
- Jurk, Diana
- Passos, João F.
- LeBrasseur, Nathan K.
- Kirkland, James L.
- Monroe, David G.
- Khosla, Sundeep
- Venue
- Journal of Clinical Investigation
- Published
- 2023-04-17
- Volume
- 133
- Issue
- 8
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC10104901
- OpenAlex
- W4321445705
- Cited by
- 81
- References
- 54
- Citations by year
- 2026: 26 · 2025: 15 · 2024: 28 · 2023: 12
- FWCI
- 14.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institute on Aging (AG062413,AG076515,AG068048,AG013925,AG063543,AG056278,AG063707)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK128552)
- National Cancer Institute (UG3CA26810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- senolysis, senescent cells, aging, age-related bone loss, osteocytes, senescence-associated secretory phenotype, osteoclasts, bone formation, senolytics, healthy aging
- MeSH terms
- Aging, Animals, Bone and Bones, Osteoclasts, Osteocytes, Cellular Senescence, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Local senolysis in aged mice only partially replicates the benefits of systemic senolysis. https://app.cochat.ai/papers/10.1172/jci162519
- The paper
- Farr, J. N., Saul, D., Doolittle, M. L., Kaur, J., Rowsey, J. L., Vos, S. J., Froemming, M. N., Lagnado, A. B., Zhu, Y., Weivoda, M., Ikeno, Y., Pignolo, R. J., Niedernhofer, L. J., Robbins, P. D., Jurk, D., Passos, J. F., LeBrasseur, N. K., Tchkonia, T., Kirkland, J. L., . . . Khosla, S. (2023). Local senolysis in aged mice only partially replicates the benefits of systemic senolysis. Journal of Clinical Investigation. https://doi.org/10.1172/jci162519
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.